<p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）在 TD Cowen 發佈給投資者的研究報告中被股票研究分析師升級為 “強力買入” 評級，Zacks.com 報道。</p>
<ul>
<li>你可能不知道的突破性動量股票</li>
</ul>
<p>其他幾家研究公司也最近對 EYPT 發表了看法。瑞穗證券在 10 月 20 日的報告中將 Eyepoint Pharmaceuticals 的目標價格設定為 28.00 美元。Weiss Ratings 在 10 月 8 日的報告中重申了對 Eyepoint Pharmaceuticals 股票的 “賣出（d-）” 評級。加拿大皇家銀行在 11 月 6 日的研究報告中將 Eyepoint Pharmaceuticals 的目標價格從 28.00 美元上調至 39.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Cantor Fitzgerald 在 11 月 25 日的研究報告中將 Eyepoint Pharmaceuticals 的股票評級提升至 “強力買入”。兩位投資分析師對該股票給予了強力買入評級，五位給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，Eyepoint Pharmaceuticals 目前的平均評級為 “買入”，平均目標價格為 30.00 美元。</p>
<p><strong>查看我們關於 EYPT 的最新報告</strong></p>
<h2>Eyepoint Pharmaceuticals 股價上漲 2.2%</h2>
<p>納斯達克代碼：EYPT 的股票在週五以 17.43 美元開盤。該公司的市值為 14.4 億美元，市盈率為-5.83，貝塔值為 1.67。Eyepoint Pharmaceuticals 的 1 年最低價為 3.91 美元，1 年最高價為 19.11 美元。該公司的 50 日移動平均價格為 13.70 美元，200 日移動平均價格為 12.03 美元。</p>
<p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）在 11 月 5 日星期三發佈了季度財報。該公司報告每股收益為（0.85 美元），低於分析師一致預期的（0.77 美元）8 美分。Eyepoint Pharmaceuticals 的淨利潤率為-485.95%，股本回報率為-76.13%。該公司在本季度的收入為 97 萬美元，而分析師預期為 333 萬美元。作為一個整體，股票分析師預測 Eyepoint Pharmaceuticals 在本年度將發佈-2.13 的每股收益。</p>
<h2>對 Eyepoint Pharmaceuticals 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Nisa Investment Advisors LLC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股比例提高了 1636.5%。Nisa Investment Advisors LLC 現在擁有 2900 股該公司的股票，價值 27000 美元，此前在此期間又購買了 2733 股。阿拉斯加州財政部在第三季度購買了 Eyepoint Pharmaceuticals 的新頭寸，價值約 50000 美元。拉塞爾投資集團有限公司在第三季度購買了 Eyepoint Pharmaceuticals 的新頭寸，價值約 76000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股比例提高了 218.3%。Tower Research Capital LLC TRC 現在擁有 8700 股該公司的股票，價值 82000 美元，此前在上個季度又收購了 5967 股。最後，R Squared Ltd 在第二季度購買了 Eyepoint Pharmaceuticals 的新股份，價值約 100000 美元。99.41% 的股票由機構投資者持有。</p>
<h2>關於 Eyepoint Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Eyepoint Pharmaceuticals, Inc 是一家生物製藥公司，專注於開發和商業化治療眼部疾病的療法。該公司的專有平台集中於持續釋放的製劑，旨在改善藥物向眼後段的輸送，解決通常需要重複玻璃體內注射或密集局部治療的情況。Eyepoint 的商業策略結合了內部銷售和市場能力與有針對性的合作伙伴關係，將其療法帶給美國的眼科醫生和視網膜專家。</p>
<p>Eyepoint 的主要產品包括 YUTIQ，一種氟氯噻噸醇玻璃體內植入物，旨在預防影響眼後段的非感染性葡萄膜炎的復發，以及 DEXYCU，一種用於眼科手術後炎症的地塞米松眼內懸浮液。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Eyepoint Pharmaceuticals 更好</li>
<li>如何投資藍籌股</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>股票平均計算器</li>
<li>耐克在收益上超出預期，但在中國面臨困難並遭遇關税</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Eyepoint Pharmaceuticals 嗎？</h2>
<p>在你考慮 Eyepoint Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場意識到之前...而 Eyepoint Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eyepoint Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

EYPT

<p>TD Cowen 將 EyePoint Pharmaceuticals 的評級上調至 “強力買入”。其他公司如瑞穗證券和加拿大皇家銀行分別設定了 28 美元和 39 美元的目標價。Cantor Fitzgerald 也給予了 “強力買入” 的評級。該股票開盤價為 17.43 美元，市值為 14.4 億美元。分析師預測該年度每股收益為 -2.13。機構投資者持有該股票的 99.41%。EyePoint 專注於眼科疾病治療，產品包括 YUTIQ 和 DEXYCU</p>

<p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) was upgraded by equities research analysts at TD Cowen to a &#34;strong-buy&#34; rating in a research note issued to investors on Friday,Zacks.com reports.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）在 TD Cowen 發佈給投資者的研究報告中被股票研究分析師升級為 “強力買入” 評級，Zacks.com 報道。</p>
</div><ul>
<li>Breakout Momentum Plays You May Not Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能不知道的突破性動量股票</li>
</ul>
</div><p>Several other research firms have also recently weighed in on EYPT. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a report on Monday, October 20th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of &#34;Buy&#34; and an average target price of $30.00.</p>
<div class="lb-trans"><p>其他幾家研究公司也最近對 EYPT 發表了看法。瑞穗證券在 10 月 20 日的報告中將 Eyepoint Pharmaceuticals 的目標價格設定為 28.00 美元。Weiss Ratings 在 10 月 8 日的報告中重申了對 Eyepoint Pharmaceuticals 股票的 “賣出（d-）” 評級。加拿大皇家銀行在 11 月 6 日的研究報告中將 Eyepoint Pharmaceuticals 的目標價格從 28.00 美元上調至 39.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Cantor Fitzgerald 在 11 月 25 日的研究報告中將 Eyepoint Pharmaceuticals 的股票評級提升至 “強力買入”。兩位投資分析師對該股票給予了強力買入評級，五位給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，Eyepoint Pharmaceuticals 目前的平均評級為 “買入”，平均目標價格為 30.00 美元。</p>
</div><p><strong>View Our Latest Report on EYPT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 EYPT 的最新報告</strong></p>
</div><h2>Eyepoint Pharmaceuticals Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 股價上漲 2.2%</h2>
</div><p>Shares of NASDAQ:EYPT opened at $17.43 on Friday. The stock has a market capitalization of $1.44 billion, a P/E ratio of -5.83 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11. The business has a 50-day moving average price of $13.70 and a two-hundred day moving average price of $12.03.</p>
<div class="lb-trans"><p>納斯達克代碼：EYPT 的股票在週五以 17.43 美元開盤。該公司的市值為 14.4 億美元，市盈率為-5.83，貝塔值為 1.67。Eyepoint Pharmaceuticals 的 1 年最低價為 3.91 美元，1 年最高價為 19.11 美元。該公司的 50 日移動平均價格為 13.70 美元，200 日移動平均價格為 12.03 美元。</p>
</div><p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. As a group, equities analysts predict that Eyepoint Pharmaceuticals will post -2.13 EPS for the current year.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）在 11 月 5 日星期三發佈了季度財報。該公司報告每股收益為（0.85 美元），低於分析師一致預期的（0.77 美元）8 美分。Eyepoint Pharmaceuticals 的淨利潤率為-485.95%，股本回報率為-76.13%。該公司在本季度的收入為 97 萬美元，而分析師預期為 333 萬美元。作為一個整體，股票分析師預測 Eyepoint Pharmaceuticals 在本年度將發佈-2.13 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Eyepoint Pharmaceuticals 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after purchasing an additional 2,733 shares during the period. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $50,000. Russell Investments Group Ltd. bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC lifted its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the last quarter. Finally, R Squared Ltd bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth approximately $100,000. 99.41% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Nisa Investment Advisors LLC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股比例提高了 1636.5%。Nisa Investment Advisors LLC 現在擁有 2900 股該公司的股票，價值 27000 美元，此前在此期間又購買了 2733 股。阿拉斯加州財政部在第三季度購買了 Eyepoint Pharmaceuticals 的新頭寸，價值約 50000 美元。拉塞爾投資集團有限公司在第三季度購買了 Eyepoint Pharmaceuticals 的新頭寸，價值約 76000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股比例提高了 218.3%。Tower Research Capital LLC TRC 現在擁有 8700 股該公司的股票，價值 82000 美元，此前在上個季度又收購了 5967 股。最後，R Squared Ltd 在第二季度購買了 Eyepoint Pharmaceuticals 的新股份，價值約 100000 美元。99.41% 的股票由機構投資者持有。</p>
</div><h2>About Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Eyepoint Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals, Inc 是一家生物製藥公司，專注於開發和商業化治療眼部疾病的療法。該公司的專有平台集中於持續釋放的製劑，旨在改善藥物向眼後段的輸送，解決通常需要重複玻璃體內注射或密集局部治療的情況。Eyepoint 的商業策略結合了內部銷售和市場能力與有針對性的合作伙伴關係，將其療法帶給美國的眼科醫生和視網膜專家。</p>
</div><p>Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.</p>
<div class="lb-trans"><p>Eyepoint 的主要產品包括 YUTIQ，一種氟氯噻噸醇玻璃體內植入物，旨在預防影響眼後段的非感染性葡萄膜炎的復發，以及 DEXYCU，一種用於眼科手術後炎症的地塞米松眼內懸浮液。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Eyepoint Pharmaceuticals</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>Stock Average Calculator</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Eyepoint Pharmaceuticals 更好</li>
<li>如何投資藍籌股</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>股票平均計算器</li>
<li>耐克在收益上超出預期，但在中國面臨困難並遭遇關税</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=EYPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eyepoint Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Eyepoint Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Eyepoint Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場意識到之前...而 Eyepoint Pharmaceuticals 並不在名單上。</p>
</div><p>While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eyepoint Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

EyePoint Pharmaceuticals（納斯達克代碼：EYPT）在 TD Cowen 的評級被上調至強力買入